

# **Summary of risk management plan for Pramipexole Orion (pramipexole) Orion Corporation**

**Date: 08.11.2017, Version 1.2**

---

This is a summary of the risk management plan (RMP) for Pramipexole Orion. The RMP details important risks of Pramipexole Orion, how these risks can be minimized, and how more information will be obtained about Pramipexole Orion's risks and uncertainties (missing information).

Pramipexole Orion's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Pramipexole Orion should be used.

Important new concerns or changes to the current ones will be included in updates of Pramipexole Orion's RMP.

## **I. The medicine and what it is used for**

Pramipexole Orion is authorised for treatment of the signs and symptoms of idiopathic Parkinson's disease in adults, alone (without levodopa) or in combination with levodopa (see SmPC for the full indication). It contains pramipexole as the active substance and it is given by mouth.

## **II. Risks associated with the medicine and activities to minimise or further characterise the risks**

Important risks of Pramipexole Orion, together with measures to minimise such risks and the proposed studies for learning more about Pramipexole Orion's risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute routine risk minimisation measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed so that immediate action can be taken as necessary. These measures constitute routine pharmacovigilance activities.

### **II.A List of important risks and missing information**

Important risks of Pramipexole Orion are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely taken. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Pramipexole Orion. Potential risks are concerns for which an association with the

use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine);

<b>List of important risks and missing information</b>	
Important identified risks	<ul style="list-style-type: none"> <li>• Binge eating, compulsive shopping, pathological gambling, hypersexuality and other impulse control behaviour</li> <li>• Inappropriate antidiuretic hormone secretion</li> <li>• Cardiac failure</li> <li>• Hallucinations and confusion</li> </ul>
Important potential risks	<ul style="list-style-type: none"> <li>• Suicide-related behaviour</li> <li>• Augmentation, post treatment worsening after withdrawal and rebound in patients with restless legs syndrome</li> <li>• Delirium/mania</li> <li>• Retinal degeneration</li> <li>• Skin melanoma</li> <li>• Fibrotic events</li> <li>• Dopamine dysregulation syndrome</li> </ul>
Missing information	<ul style="list-style-type: none"> <li>• None</li> </ul>

## **II.B Summary of important risks**

The safety information in the proposed Product Information is aligned to the reference medicinal product.

## **II.C Post-authorisation development plan**

There are no studies required for Pramipexole Orion.